Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) is set to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect Maravai LifeSciences to post earnings of ($0.03) per share for the quarter. Maravai LifeSciences has set its FY 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. The business had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $8.97 on Monday. Maravai LifeSciences has a 52 week low of $4.52 and a 52 week high of $16.62. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $8.04 and its 200 day simple moving average is $6.69. The firm has a market capitalization of $2.26 billion, a PE ratio of -9.97 and a beta of 0.03.

Analyst Upgrades and Downgrades

Several research firms recently commented on MRVI. Stifel Nicolaus decreased their price objective on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, February 23rd. Royal Bank of Canada upped their target price on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, February 23rd. Finally, Craig Hallum began coverage on shares of Maravai LifeSciences in a report on Wednesday, April 10th. They issued a “buy” rating and a $15.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Moderate Buy” and an average target price of $11.56.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.